MILLIPLEX^® Human RANKL Singleplex

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Quantify RANKL in human serum, plasma, or tissue culture supernatant samples.Analyte included: RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features:- Singleplex magnetic bead-based assay for targeted RANKL quantification- Utilizes Luminex^® xMAP^® technology for high-throughput and reproducible results- Compatible with human serum, plasma, and tissue culture supernatants- High sensitivity and specificity for low-abundance detection- Includes all necessary reagents and standards for streamlined workflow- Verified for precision, reproducibility, and minimal cross-reactivityBenefits:- Enables focused analysis of RANKL in bone metabolism and immune signaling research- Ideal for studies on osteoporosis, arthritis, and cancer-related bone loss- Reduces sample volume requirements while delivering reliable data- Saves time and cost compared to traditional ELISA methods- Supports both basic and translational research in skeletal biology

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) is a pivotal biomarker involved in bone metabolism, immune regulation, and neuroinflammation. Its expression reflects osteoclast activity and has implications in neurodegenerative conditions where bone-immune-brain interactions are relevant. Measurement of RANKL in human samples supports research into neurological disorders, autoimmune diseases, and bone-related pathologies. This panel enables sensitive and specific quantification of RANKL, facilitating translational studies and therapeutic monitoring in neuroscience and immunology.